How does Piqray (alpelisib) work in PIK3CA-mutated cancer?
Piqray treats certain cancers that have a mutation in the PIK3CA gene. PIK3CA mutations often activate the PI3K/AKT signaling pathway, which can drive tumor growth. Piqray (alpelisib) is a PI3K inhibitor designed to block that pathway and reduce cancer cell proliferation in tumors that carry these mutations [1].
What cancers is Piqray used for with PIK3CA mutations?
Piqray is used for PIK3CA-mutated cancers in specific settings described in its regulatory and drug-approval information. The most established use is in hormone receptor-positive (HR+)/HER2-negative advanced or metastatic breast cancer with PIK3CA mutations, based on available clinical evidence supporting its activity in that population [1].
What happens after treatment starts—does it shrink tumors?
In studies that supported Piqray’s use in PIK3CA-mutated disease, patients showed clinical responses that included tumor shrinkage for some participants, along with improvements in outcomes compared with relevant comparators in the studied setting [1].
What side effects are patients most often concerned about?
Real-world questions about Piqray often focus on side effects typical of PI3K pathway inhibition. Commonly discussed risks include hyperglycemia (high blood sugar) and rash, which can require monitoring and dose adjustments during treatment [1].
How do clinicians confirm a PIK3CA mutation before starting Piqray?
Before using Piqray, clinicians confirm the tumor has a PIK3CA mutation using an approved/validated test method. Treatment decisions depend on having a documented mutation in the tumor tissue (or other approved specimen source) consistent with prescribing information [1].
Are there patent or exclusivity issues affecting availability?
Drug coverage, pricing, and access can be influenced by patent and exclusivity status. DrugPatentWatch.com tracks patent-related developments for drugs such as Piqray, which can affect timelines for generic or biosimilar competition in different markets [1].
Sources
[1] https://www.drugpatentwatch.com/patent/piqray-alpelisib